OPTImized coronary interventions eXplaIn the bEst cliNical outcomEs (OPTI-XIENCE) study. Rationale and study design-Reference-Cited by-同舟云学术

OPTImized coronary interventions eXplaIn the bEst cliNical outcomEs (OPTI-XIENCE) study. Rationale and study design

Published:2024-02 Issue: Volume:59 Page:93-98
ISSN:1553-8389
Container-title:Cardiovascular Revascularization Medicine
language:en
Short-container-title:Cardiovascular Revascularization Medicine

Author:

Moreno Raul,Baptista Sergio Bravo,Valencia Jose,Gomez-Menchero Antonio,Bouisset Frederic,Ruiz-Arroyo Jose Ramon,Bento Angela,Besutti Matthieu,Jimenez-Valero Santiago,Rivero-Santana Borja,Olhmann Patrick,Santos Miguel,Vaquerizo Beatriz,Cuissetm Thomas,Lemoine Julien,Pinar Eduardo,Fiarresga Antonio,Urbano Cristobal,Marliere Stephanie,Braga Carlos,Amat-Santos Ignacio,Morgado Gonçalo,Sarnago Fernando,Telleria Miren,Van Belle Eric,Díaz-Fernandez Jose,Borrego Juan Caballero,Amabile Nicolas,Meneveau Nicolas

Funder

Spanish Society of Cardiology

Abbott Laboratories

Boston Scientific Corporation

Publisher

Elsevier BV

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Reference46 articles.

1. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial;Kedhi;Lancet.,2010

2. SPIRIT IV Investigators. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease;Stone;N Engl J Med,2010

3. ENDEAVOR IV Investigators. The “final” 5-year follow-up from the ENDEAVOR IV trial comparing a zotarolimus-eluting stent with a paclitaxel-eluting stent;Kirtane;JACC Cardiovasc Interv,2013

4. TUXEDO–India investigators. Paclitaxel-eluting versus everolimus-eluting coronary stents in diabetes;Kaul;N Engl J Med,2015

5. Clinical outcomes in patients with ST-segment elevation myocardial infarction treated with everolimus-eluting stents versus bare-metal stents (EXAMINATION): 5-year results of a randomised trial;Sabaté;Lancet.,2016